Cancer gene therapy: Combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect

Abstract

Current anti-cancer modalities such as surgery, chemo- and radiation therapies have only limited success in cancer treatment. Gene therapy is a promising new tool to improve outcomes. In this review, first we summarize the various strategies to kill tumor cells, and then focus on the bystander effect of gene therapy. A variety of strategies, such as gene-directed enzyme pro-drug therapy, activation of an anti-tumor immune attack, application of replication-competent and oncolytic viral vectors, tumor-specific as well as radiation- and hypoxiainduced gene expression, might be applied to target tumor cells. We put special emphasis on the combination of these approaches with local tumor irradiation. Using the available vector systems, only a small portion of cancer cells contains the therapeutic genes under clinical situations. However, cells directly targeted by gene therapy will transfer death signals to neighboring cancer cells. This bystander cell killing improves the efficiency of cancer gene therapy. Death signals are delivered by cell-to-cell communication through gap junction intercellular contacts, release of toxic metabolites into the neighborhood or to larger distances, phagocytosis of apoptotic bodies, and the activation of the immune system. Bystander cell killing can be enhanced by the introduction of gap junction proteins into cells, by further activating the immune system with immune-stimulatory molecules, or by introducing genes that help the transfer of cytotoxic genes and/or metabolites into bystander cells. In conclusion, although bystander cell killing can improve therapeutic effects, there should be additional developments in cancer gene therapy for a more efficient clinical application.

Heavy-Ion Microbeam Irradiation Induces Bystander Killing of Human Cells

“…On the other, we have also demonstrated that attenuated bystander responses occur independently of Bcl-2 overexpression in cervical cancer cells. Enhancing bystander response of tumor cells would provide a novel potential radiotherapeutic regimen where lower doses and/or smaller tumor target volume could be irradiated (Lumniczky & Safrany, 2006;Hamada et al, 2007). Azzam …”

Adenoviral Vectors: Potential and Challenges as a Gene Delivery System

“…Although direct toxicity is imparted by GDEPTmediated cell death, there is also significant growth inhibition/killing of uninfected neighboring tumor cells due to the transfer of the toxic drug. The causes of this event are hypothesized to involve transfer via gap junctions or diffusion and stimulation of an antitumor response against lysed tumor cells (Lumniczky & Safrany, 2006). Replication-defective AdV were initially used in GDEPT but demonstrated poor anti-tumor efficacy.…”

Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas

“…One possibility is the development of viral vectors, which can either replicate in a tumor-specific manner or the expression of the therapeutic gene is driven by tumor specific promoters. 3 Further improvement might be the design of dCK mutants, which have an increased efficiency toward gemcitabine phosphorylation. 47 …”

“…Malignant gliomas are among tumors considered relatively radioresistant. 1,2 One possible way to overcome tumor radioresistance is to use a gene directed enzyme prodrug therapy (GDEPT) approach, 3 where the prodrug is a radiosensitizing chemotherapeutic agent.…”